VANCOUVER, BC — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including… Read More
$2.3M revenues (unaudited) in Q4 2023, representing 123% increase quarter over quarter (“QoQ”) Optimized and scaled up manufacturing processes over the last 12 months to meet increasing demand Third consecutive… Read More
Financing led by premier psychedelics focused investment fund Negev Capital VANCOUVER, BC — Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company,… Read More
EDMONTON, AB — (BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study… Read More
Molecular You is thrilled to announce the appointment of Jim Kean as CEO to spearhead the company’s expansion efforts in the United States. VANCOUVER, BC — (GLOBAL NEWSWIRE) — Molecular… Read More
